Abstract Library

#2876 Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)

Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,

Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,

#2185 Nonfunctional Pancreatic Neuroendocrine Tumor (NF PNET) Imaging and Evaluation Using 18F-FDG and 68Ga- DOTANOC-PET/CT: Initial Data of a Prospective Study

Introduction: Predicting aggressive behavior of NF PNET still remains controversial. It is known that lymph node metastases are rare but possible also on small (1-2 cm) NF-PNET. Positive 18F-FDG-PET/CT avidity is associated with poor prognosis in NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kauhanen O

Authors: Majala S, Seppänen H, Kemppainen J, Arola J, Schalin-Jäntti C,

Keywords: pancreatic neuroendocrine tumors, nonfunctional, incidentaloma, positron emission tomography, diagnosis,